Currently, there are 165.84M common shares owned by the public and among those 158.61M shares have been available to trade.
The company’s stock has a 5-day price change of 9.75% and -13.70% over the past three months. INVZ shares are trading -60.77% year to date (YTD), with the 12-month market performance down to -68.69% lower. It has a 12-month low price of $0.83 and touched a high of $4.39 over the same period. INVZ has an average intraday trading volume of 1.82 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 8.36%, -4.58%, and -35.68% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Innoviz Technologies Ltd (NASDAQ: INVZ) shares accounts for 40.00% of the company’s 165.84M shares outstanding.
It has a market capitalization of $164.60M and a beta (3y monthly) value of 0.98. The earnings-per-share (ttm) stands at -$0.77. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.74% over the week and 6.48% over the month.
Earnings per share for the fiscal year are expected to increase by 22.85%, and 16.78% over the next financial year.
Looking at the support for the INVZ, a number of firms have released research notes about the stock. Goldman stated their Neutral rating for the stock in a research note on July 11, 2024, with the firm’s price target at $2.25-$1. Rosenblatt coverage for the Innoviz Technologies Ltd (INVZ) stock in a research note released on October 25, 2022 offered a Neutral rating with a price target of $5. Berenberg was of a view on September 28, 2022 that the stock is Buy, while JP Morgan gave the stock Overweight rating on September 20, 2022, issuing a price target of $22. Goldman on their part issued Buy rating on November 17, 2021.
